Does gene therapy become pharmacotherapy? - Wikidata - awgldk - TriplyDB

Does gene therapy become pharmacotherapy?

Does gene therapy become pharmacotherapy?

http://www.wikidata.org/entity/Q36075155

about

Therapeutic regulation of gene expression in the inner ear using RNA interference.Nucleic acid drugs for prevention of cardiac rejection.

P2860

Q37507085-8C509836-53F0-4937-AECD-66385ACE2211 Q37672986-8119CDD7-36EB-4145-87AD-5017FBAB9FDB

P2860

Does gene therapy become pharmacotherapy?

http://www.wikidata.org/entity/Q36075155

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Does gene therapy become pharmacotherapy?

@ast

Does gene therapy become pharmacotherapy?

@en

type

label

Does gene therapy become pharmacotherapy?

@ast

Does gene therapy become pharmacotherapy?

@en

prefLabel

Does gene therapy become pharmacotherapy?

@ast

Does gene therapy become pharmacotherapy?

@en

P1433

Q36075155-4CF2A79B-F776-4FC8-9E47-F5D962AD3923

P1476

Q36075155-E1666DD6-1DF1-49AF-8867-D55847464D47

P2093

Q36075155-147815FE-AD84-4BB0-B52B-A4347A95C278

Q36075155-B6CCFBD4-1F90-4F7E-A4A7-50F35DC70BE3

Q36075155-E8D3722D-DD41-4E1D-A24D-95A4A6C48502

P2860

Q36075155-00BBCB9C-917A-4FE0-A782-8E72F11E67AC

Q36075155-0CE325A8-A75F-4A1E-AC57-88766F1F3B56

Q36075155-1252D443-880D-446A-AA91-AAF57DC47D01

Q36075155-16ABF24C-D91A-4F6E-B061-7B93E028F1C3

Q36075155-18AC1D48-FC32-4049-BB2F-1A939892DC98

Q36075155-1A194FDC-F7DC-43BF-9074-CBA87FD2420F

Q36075155-1F73C039-5EE3-4239-AED2-A9269A1F1621

Q36075155-25393399-BF5B-46C0-ADB6-EE3B548E62B3

Q36075155-273015E5-F854-4E6D-B8B6-E86E54575CA7

Q36075155-34FEC626-A4C6-4C72-9963-566F68C8EDD3

P304

Q36075155-5A31960D-A4F4-40E0-B35E-43383A9319AA

P31

Q36075155-CD0A53E9-56C5-434A-B3C8-857A3DF46AE8

P356

Q36075155-C37AC869-8BEF-4DAA-A959-EDA3994643F4

P433

Q36075155-E580277F-14D0-443D-983E-C01F1973B2C2

P478

Q36075155-64EA76CE-C71B-49BD-84E4-655DF099155E

P577

Q36075155-658D8943-423E-412E-AA1A-5BB2CF663653

P5875

Q36075155-8F951E2F-E767-4300-96B8-7DABD76AC298

P698

Q36075155-87C923ED-8949-499F-9E83-9BC2A33F8AE2

P921

Q36075155-72CB9AEE-7CD7-483F-9F41-D733FE81C72D

Q36075155-A4803450-F43C-42A8-8900-649031F8DF8E

P356

EXPPHYSIOL.2005.030403

P1433

Experimental Physiology

P1476

Does gene therapy become pharmacotherapy?

@en

P2093

Motokuni Aoki

http://www.w3.org/2001/XMLSchema#string

Ryuichi Morishita

http://www.w3.org/2001/XMLSchema#string

Toshio Ogihara

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes.

Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy.

Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.

Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.

A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the K

Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.

Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.

P304

307-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1113/EXPPHYSIOL.2005.030403

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7957450

http://www.w3.org/2001/XMLSchema#string

P698

15778409

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy